RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Save

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

Save

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.

Psoriatic Disease Management - RNL 2021 Highlights

Save

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Save

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Great Associations (3.19.2021)

Save

Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.

Apremilast Equals MTX in Palmoplantar Psoriasis

Save

Palmoplantar psoriasis (PPP) is a therapeutically challenging variant of psoriasis; nonetheless, a prospective, randomized, active-controlled trial from India suggests that apremilast is effective and safe in patients with PPP.

Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures

Save

JAMA Dermatology has published a Danish national cohort study showing that potent topical corticosteroid use was associated with an increased risk of osteoporosis and major osteoporotic fractures with a dose-response association for cumulative use.

MDA-5 Antibodies and Juvenile Dermatomyositis

Save

A multicentre, retrospective study examined MSA profiles (by immunoprecipitation) from 96 juvenile idiopathic inflammatory myopathies (JIIM) at nine pediatric rheumatology centres in Japan. MSA were found in 85 of 96 cases with over 90% of patients having one of the following three MSA

Enthesitis Responses to Secukinumab in Spondylitis Patients

Save

Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Save

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Save

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Lung Preservation with Tocilizumab in Early Systemic Sclerosis

Save

Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).

Dr. Shenoi Suspect autoinflammatory Dz: patterned fevers MSK and skin involvement Serositis Other - aphthous ulcers, CNS (stroke, basal ganglia calcification,) ILD, LN, lipodystrophy) ethnicity (FMF or Mediterranean) Family Hx -- Testing options! #RWCS2021 @RheumNow @RWCSmtg https://t.co/DZk4hsxbk4

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Save

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.